Osteoarthritis (OA) is the most common cause of chronic pain in dogs and can significantly impact their mobility and quality of life. The disease can begin in very young dogs and it progresses over time. Disease-modifying osteoarthritis drugs (DMOADs) are one class of drugs that can actually slow progression of the disease by reducing loss of cartilage and improving joint health. Adequan (polysulfated glycosaminoglycan) is a commercially available DMOAD that is commonly used early in the course of the disease to proactively slow the loss of cartilage in the dog's joints. There are recommended protocols to achieve the best result. In this segment Dr. James Gaynor - a veterinary pain management expert - addresses a commonly asked question about the dosing of Adequan and shares his approach to the use of this drug in dogs. Learn more about arthritis pain management: https://bit.ly/VetVine_Gaynor

You might also like

The Skinny On Pyoderma - The Most Common Bacterial Infection Of The Skin

08/05/2025

Join us in this live and interactive webinar - the second segment of a 4-part series on common and f...

Read More

Signs and symptoms of Pug Dog Encephalitis - From subtle to severe

07/12/2023

Dr. Rebecca Windsor, a veterinary neurologist, explains some of the more common signs and symptoms o...

Read More

Discospondylitis as a cause of back pain

06/20/2023

Arthritis of the spine is a very common problem in companion animals however it is one of the most...

Read More

What else can we do beyond pain control for dogs with osteoarthritis?

06/01/2023

What else - beyond pain control - can we do for dogs living with osteoarthritis? Dr. James Gaynor an...

Read More

Joint injections for arthritis in dogs - which one and how often?

05/23/2023

Successful management of a patient with arthritis requires that we address several things includin...

Read More

Recognition and Management of Neuropathic Pain

05/17/2023

Presented by Rebecca Windsor, DVM, DACVIM (Neurology / Neurosurgery) Access an evaluation / Ear...

Read More